[Agranulocytosis after application of silver sulfadiazine in a 2-month old infant].
BACKGROUND
A granulocytosis associated with the use of silver sulfadiazine has been described in burn patients. This agranulocytosis may be due to either an allergic reaction or a bone marrow toxicity by silver sulfadiazine.


METHODS
A 1-month old baby was hospitalized in pediatric intensive care unit after a stage one repair of a tracheoesophegeal fistula. Gastroesophageal reflux and tracheomalacia appeared in the post operative period. When she was 2-months old, she developed a perineal erythema. A topical therapy was begun, with daily applications of silver sulfadiazine and ketoconazole. Five days later, agranulocytosis (granulocytes = 0.21 x 10(9).L-1) occurred. Silver sulfadiazine therapy was immediately stopped. Granulocyte count returned to normal over a few days. No other etiology than silver sulfadiazine could be found to explain agranulocytosis. The small surface of administration, the chronology of the events and the rapid correction of the disorders after silver sulfadiazine interruption argued for an immuno-allergic reaction to this drug. Medical problems were easily controlled and the patient recovered well.


CONCLUSIONS
This event occurred when sulfadiazine was applied in a small cutaneous area in a young baby. This may be an argument for an allergic reaction; alternatively, it could be explained by an increased cutaneous absorption of a cytotoxic drug in younger people.
Viala
J
J
Service de réanimation pédiatrique, hôpital de Bicêtre, Le Kremlin-Bicêtre, France.
Simon
L
L
Le Pommelet
C
C
Philippon
L
L
Devictor
D
D
Huault
G
G
D000380:Agranulocytosis / Q000139:chemically induced*; D000891:Anti-Infective Agents, Local / Q000009:adverse effects* / Q000627:therapeutic use; D004890:Erythema / Q000188:drug therapy; D005260:Female; D006801:Humans; D007223:Infant; D012837:Silver Sulfadiazine / Q000009:adverse effects* / Q000627:therapeutic use
D000891:Anti-Infective Agents, Local; D012837:Silver Sulfadiazine
Agranulocytose après application de sulfadiazine argentique chez un nourrisson de 2 mois.